Nuclear hormone receptors in podocytes

Cell and Bioscience

Volumn 2, Issue 1, 2012, Pages

  Khurana, Simran ^a   Bruggeman, Leslie A ^b   Kao, Hung Ying ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Diabetic and non diabetic nephropathy; Focal segmental glomerulosclerosis (FSGS); Glucocorticoid receptor; Mineralocorticoid receptor; Podocyte injury; Proteinuria

Indexed keywords

ANIMALIA;

EID: 84872315073     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-2-33     Document Type: Review

References (138)

1. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, et al. The nuclear receptor superfamily: the second decade. Cell 1995, 83(6):835-839. 10.1016/0092-8674(95)90199-X, 8521507.
2. Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu Rev Physiol 2003, 65:261-311. 10.1146/annurev.physiol.65.092101.142528, 12518001.
3. Germain P, Staels B, Dacquet C, Spedding M, Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol Rev 2006, 58(4):685-704. 10.1124/pr.58.4.2, 17132848.
4. Luisi B, Freedman L. Nuclear receptors. Dymer, dymer binding tight. Nature 1995, 375(6530):359-360. 10.1038/375359a0, 7760925.
5. Luisi BF, Schwabe JW, Freedman LP. The steroid/nuclear receptors: from three-dimensional structure to complex function. Vitam Horm 1994, 49:1-47.
6. Schwabe JW. Transcriptional control: how nuclear receptors get turned on. Curr Biol 1996, 6(4):372-374. 10.1016/S0960-9822(02)00498-0, 8723335.
7. Schwabe JW, Teichmann SA. Nuclear receptors: the evolution of diversity. Sci STKE 2004, 2004(217):pe4.
8. Warnmark A, Treuter E, Wright AP, Gustafsson JA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol 2003, 17(10):1901-1909. 10.1210/me.2002-0384, 12893880.
9. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998, 95(6):2920-2925. 10.1073/pnas.95.6.2920, 19670, 9501191.
10. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103(6):843-852. 10.1016/S0092-8674(00)00188-4, 11136970.
11. Vegeto E, Allan GF, Schrader WT, Tsai MJ, McDonnell DP, O'Malley BW. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell 1992, 69(4):703-713. 10.1016/0092-8674(92)90234-4, 1586949.
12. Zhang X, Jeyakumar M, Petukhov S, Bagchi MK. A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 1998, 12(4):513-524. 10.1210/me.12.4.513, 9544987.
13. Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW. Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. Blood 2010, 115(1):38-46. 10.1182/blood-2009-07-230698, 2803690, 19861679.
14. Hu X, Lazar MA. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 1999, 402(6757):93-96. 10.1038/47069, 10573424.
15. Nagy L, Kao HY, Love JD, Li C, Banayo E, Gooch JT, Krishna V, Chatterjee K, Evans RM, Schwabe JW. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev 1999, 13(24):3209-3216. 10.1101/gad.13.24.3209, 317208, 10617570.
16. Perissi V, Staszewski LM, McInerney EM, Kurokawa R, Krones A, Rose DW, Lambert MH, Milburn MV, Glass CK, Rosenfeld MG. Molecular determinants of nuclear receptor-corepressor interaction. Genes Dev 1999, 13(24):3198-3208. 10.1101/gad.13.24.3198, 317209, 10617569.
17. Hayakawa T, Nakayama J. Physiological roles of class I HDAC complex and histone demethylase. J Biomed Biotechnol 2011, 2011:129383. 2964911, 21049000.
18. Cunliffe VT. Eloquent silence: developmental functions of Class I histone deacetylases. Curr Opin Genet Dev 2008, 18(5):404-410. 10.1016/j.gde.2008.10.001, 2671034, 18929655.
19. Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995, 378(6558):681-689. 10.1038/378681a0, 7501014.
20. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000, 21(10):381-388. 10.1016/S0165-6147(00)01548-0, 11050318.
21. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol Cell 2000, 5(2):289-298. 10.1016/S1097-2765(00)80424-4, 10882070.
22. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000, 5(1):173-179. 10.1016/S1097-2765(00)80413-X, 10678179.
23. Wagner RL, Apriletti JW, McGrath ME, West BL, Baxter JD, Fletterick RJ. A structural role for hormone in the thyroid hormone receptor. Nature 1995, 378(6558):690-697. 10.1038/378690a0, 7501015.
24. Roeder RG. The role of general initiation factors in transcription by RNA polymerase II. Trends Biochem Sci 1996, 21(9):327-335.
25. Jin L, Li Y. Structural and functional insights into nuclear receptor signaling. Adv Drug Deliv Rev 2010, 62(13):1218-1226. 10.1016/j.addr.2010.08.007, 2991384, 20723571.
26. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 387(6634):733-736. 10.1038/42750, 9192902.
27. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997, 387(6634):677-684. 10.1038/42652, 9192892.
28. McInerney EM, Rose DW, Flynn SE, Westin S, Mullen TM, Krones A, Inostroza J, Torchia J, Nolte RT, Assa-Munt N, et al. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 1998, 12(21):3357-3368. 10.1101/gad.12.21.3357, 317227, 9808623.
29. Bulynko YA, O'Malley BW. Nuclear Receptor Coactivators: Structural and Functional Biochemistry. Biochemistry 2010, 2010:2010.
30. Chen JD. Steroid/nuclear receptor coactivators. Vitam Horm 2000, 58:391-448.
31. Chen S, Johnson BA, Li Y, Aster S, McKeever B, Mosley R, Moller DE, Zhou G. Both coactivator LXXLL motif-dependent and -independent interactions are required for peroxisome proliferator-activated receptor gamma (PPARgamma) function. J Biol Chem 2000, 275(6):3733-3736. 10.1074/jbc.275.6.3733, 10660518.
32. Vo N, Goodman RH. CREB-binding protein and p300 in transcriptional regulation. J Biol Chem 2001, 276(17):13505-13508.
33. McKenna NJ, O'Malley BW. Minireview: nuclear receptor coactivators-an update. Endocrinology 2002, 143(7):2461-2465. 10.1210/en.143.7.2461, 12072374.
34. Glass CK, Rose DW, Rosenfeld MG. Nuclear receptor coactivators. Curr Opin Cell Biol 1997, 9(2):222-232. 10.1016/S0955-0674(97)80066-X, 9069256.
35. Metivier R, Reid G, Gannon F. Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep 2006, 7(2):161-167. 10.1038/sj.embor.7400626, 1369254, 16452926.
36. Fernandes I, White JH. Agonist-bound nuclear receptors: not just targets of coactivators. J Mol Endocrinol 2003, 31(1):1-7. 10.1677/jme.0.0310001, 12914520.
37. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, Chambon P. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011, 145(2):224-241. 10.1016/j.cell.2011.03.027, 21496643.
38. Oetting A, Yen PM. New insights into thyroid hormone action. Best Pract Res Clin Endocrinol Metab 2007, 21(2):193-208. 10.1016/j.beem.2007.04.004, 17574003.
39. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Nuclear receptors and their coregulators in kidney. Kidney Int 2005, 68(6):2444-2461. 10.1111/j.1523-1755.2005.00721.x, 16316322.
40. Johansson L, Bavner A, Thomsen JS, Farnegardh M, Gustafsson JA, Treuter E. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Mol Cell Biol 2000, 20(4):1124-1133. 10.1128/MCB.20.4.1124-1133.2000, 85230, 10648597.
41. Jimenez-Lara AM, Aranda A. Interaction of vitamin D and retinoid receptors on regulation of gene expression. Horm Res 2000, 54(5-6):301-305.
42. Glass CK, Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10(5):365-376. 10.1038/nri2748, 20414208.
43. Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002, 13(12):3005-3015. 10.1097/01.ASN.0000039661.06947.FD, 12444221.
44. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol 2007, 17(9):428-437. 10.1016/j.tcb.2007.06.006, 17804239.
45. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte?. Kidney Int 2010, 77(7):571-580. 10.1038/ki.2009.424, 19924101.
46. Chuang PY, He JC. Signaling in regulation of podocyte phenotypes. Nephron Physiol 2009, 111(2):p9-p15. 10.1159/000191075, 2881215, 19142027.
47. Kawachi H, Suzuki K, Miyauchi N, Hashimoto T, Otaki Y, Shimizu F. Slit diaphragm dysfunction in proteinuric states: identification of novel therapeutic targets for nephrotic syndrome. Clin Exp Nephrol 2009, 13(4):275-280. 10.1007/s10157-009-0162-x, 19266252.
48. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva R, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998, 1(4):575-582. 10.1016/S1097-2765(00)80057-X, 9660941.
49. Putaala H, Soininen R, Kilpelainen P, Wartiovaara J, Tryggvason K. The murine nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 2001, 10(1):1-8. 10.1093/hmg/10.1.1, 11136707.
50. Cooper ME, Mundel P, Boner G. Role of nephrin in renal disease including diabetic nephropathy. Semin Nephrol 2002, 22(5):393-398. 10.1053/snep.2002.34724, 12224046.
51. Dai S, Wang Z, Pan X, Wang W, Chen X, Ren H, Hao C, Han B, Chen N. Functional analysis of promoter mutations in the ACTN4 and SYNPO genes in focal segmental glomerulosclerosis. Nephrol Dial Transplant 2010, 25(3):824-835. 10.1093/ndt/gfp394, 19666657.
52. Vinai M, Waber P, Seikaly MG. Recurrence of focal segmental glomerulosclerosis in renal allograft: an in-depth review. Pediatr Transplant 2010, 14(3):314-325. 10.1111/j.1399-3046.2009.01261.x, 20519016.
53. Fernandez Fresnedo G, Sanchez Plumed J, Arias M, Del Castillo Caba D, Lopez Oliva MO. Progression factors in chronic kidney disease. Non-immunological mechanisms. Nefrologia 2009, 29(Suppl 1):16-24.
54. Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008, 12(4):233-242. 10.1007/s10157-008-0034-9, 18317876.
55. Kiyomoto H, Rafiq K, Mostofa M, Nishiyama A. Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury. J Pharmacol Sci 2008, 108(4):399-405. 10.1254/jphs.08R02CR, 19057124.
56. Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE. Glucocorticoids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int 2005, 68(6):2473-2483. 10.1111/j.1523-1755.2005.00723.x, 16316324.
57. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G. Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 2006, 104(4):e158-e168. 10.1159/000094967, 16902320.
58. Ren S, Xin C, Beck KF, Saleem MA, Mathieson P, Pavenstadt H, Pfeilschifter J, Huwiler A. PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun 2005, 338(4):1818-1824. 10.1016/j.bbrc.2005.10.158, 16288986.
59. Suzuki A, Ito T, Imai E, Yamato M, Iwatani H, Kawachi H, Hori M. Retinoids regulate the repairing process of the podocytes in puromycin aminonucleoside-induced nephrotic rats. J Am Soc Nephrol 2003, 14(4):981-991. 10.1097/01.ASN.0000057857.66268.8F, 12660332.
60. Fujii Y, Khoshnoodi J, Takenaka H, Hosoyamada M, Nakajo A, Bessho F, Kudo A, Takahashi S, Arimura Y, Yamada A, et al. The effect of dexamethasone on defective nephrin transport caused by ER stress: a potential mechanism for the therapeutic action of glucocorticoids in the acquired glomerular diseases. Kidney Int 2006, 69(8):1350-1359.
61. Kummer S, Jeruschke S, Wegerich LV, Peters A, Lehmann P, Seibt A, Mueller F, Koleganova N, Halbenz E, Schmitt CP, et al. Estrogen receptor alpha expression in podocytes mediates protection against apoptosis in-vitro and in-vivo. PLoS One 2011, 6(11):e27457. 10.1371/journal.pone.0027457, 3214053, 22096576.
62. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, Koch A, Hamar P, Amann K, Ritz E. Beneficial Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp Rats. J Am Soc Nephrol 2004, 15(2):348-358. 10.1097/01.ASN.0000105993.63023.D8, 14747381.
63. Catanuto P, Doublier S, Lupia E, Fornoni A, Berho M, Karl M, Striker GE, Xia X, Elliot S. 17 beta-estradiol and tamoxifen upregulate estrogen receptor beta expression and control podocyte signaling pathways in a model of type 2 diabetes. Kidney Int 2009, 75(11):1194-1201. 10.1038/ki.2009.69, 19279558.
64. Doublier S, Lupia E, Catanuto P, Periera-Simon S, Xia X, Korach K, Berho M, Elliot SJ, Karl M. Testosterone and 17beta-estradiol have opposite effects on podocyte apoptosis that precedes glomerulosclerosis in female estrogen receptor knockout mice. Kidney Int 2011, 79(4):404-413. 10.1038/ki.2010.398, 20962747.
65. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes. Kidney Int 2006, 70(6):1038-1045. 10.1038/sj.ki.5001655, 16837924.
66. Yamauchi K, Takano Y, Kasai A, Hayakawa K, Hiramatsu N, Enomoto N, Yao J, Kitamura M. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int 2006, 70(5):892-900. 10.1038/sj.ki.5001625, 16820792.
67. Wada T, Pippin JW, Nangaku M, Shankland SJ. Dexamethasone's prosurvival benefits in podocytes require extracellular signal-regulated kinase phosphorylation. Nephron Exp Nephrol 2008, 109(1):e8-e19. 10.1159/000131892, 18480613.
68. Bertocchio JP, Warnock DG, Jaisser F. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney Int 2011, 79(10):1051-1060. 10.1038/ki.2011.48, 21412221.
69. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007, 49(2):355-364.
70. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, Yukimura T, Shokoji T, Kimura S, Kiyomoto H, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 2005, 16(3):703-711. 10.1681/ASN.2004080649, 2572705, 15647337.
71. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006, 47(6):1084-1093. 10.1161/01.HYP.0000222003.28517.99, 16636193.
72. Nishiyama A, Kobori H, Konishi Y, Morikawa T, Maeda I, Okumura M, Kishida M, Hamada M, Nagai Y, Nakagawa T, et al. Mineralocorticoid receptor blockade enhances the antiproteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther 2010, 332(3):1072-1080. 10.1124/jpet.109.158113, 2835438, 19940106.
73. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47(11):1936-1939. 10.1007/s00125-004-1542-0, 15551047.
74. Nagase M. Activation of the aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol 2010, 14(4):303-314. 10.1007/s10157-010-0298-8, 20533072.
75. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000, 278(4):F667-F675.
76. Sivarajah A, Chatterjee PK, Hattori Y, Brown PA, Stewart KN, Todorovic Z, Mota-Filipe H, Thiemermann C. Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat. Med Sci Monit 2002, 8(12):BR532-BR539.
77. Zhou Y, Kong X, Zhao P, Yang H, Chen L, Miao J, Zhang X, Yang J, Ding J, Guan Y. Peroxisome proliferator-activated receptor-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int 2011, 79(12):1302-1311. 10.1038/ki.2011.17, 21368746.
78. Mori K, Mukoyama M, Nakao K. PPAR-alpha transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice. Kidney Int 2011, 79(12):1274-1276. 10.1038/ki.2011.36, 21625258.
79. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995, 270(22):12953-12956. 10.1074/jbc.270.22.12953, 7768881.
80. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 2003, 23(4):267-276. 10.1159/000072088, 12840602.
81. Collino M, Patel NS, Lawrence KM, Collin M, Latchman DS, Yaqoob MM, Thiemermann C. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int 2005, 68(2):529-536. 10.1111/j.1523-1755.2005.00430.x, 16014029.
82. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, Fogo AB. PPAR-gamma agonist protects podocytes from injury. Kidney Int 2007, 71(12):1232-1239. 10.1038/sj.ki.5002248, 17457378.
83. Mendelsohn C, Larkin S, Mark M, LeMeur M, Clifford J, Zelent A, Chambon P. RAR beta isoforms: distinct transcriptional control by retinoic acid and specific spatial patterns of promoter activity during mouse embryonic development. Mech Dev 1994, 45(3):227-241. 10.1016/0925-4773(94)90010-8, 8011555.
84. Mendelsohn C, Lohnes D, Decimo D, Lufkin T, LeMeur M, Chambon P, Mark M. Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development 1994, 120(10):2749-2771.
85. Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, Alique M, Chen S, Ziyadeh FN, la Cruz MC I-D, Rodriguez J, Nieto E, Orellana JM, et al. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol 2003, 139(4):823-831. 10.1038/sj.bjp.0705311, 1573906, 12813006.
86. Xu Q, Lucio-Cazana J, Kitamura M, Ruan X, Fine LG, Norman JT. Retinoids in nephrology: promises and pitfalls. Kidney Int 2004, 66(6):2119-2131. 10.1111/j.1523-1755.2004.66002.x, 15569301.
87. He JC, Lu TC, Fleet M, Sunamoto M, Husain M, Fang W, Neves S, Chen Y, Shankland S, Iyengar R, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007, 18(1):93-102. 10.1681/ASN.2006070727, 3197239, 17182884.
88. Ratnam KK, Feng X, Chuang PY, Verma V, Lu TC, Wang J, Jin Y, Farias EF, Napoli JL, Chen N, et al. Role of the retinoic acid receptor-alpha in HIV-associated nephropathy. Kidney Int 2011, 79(6):624-634. 10.1038/ki.2010.470, 3050085, 21150871.
89. Zhong Y, Wu Y, Liu R, Li Z, Chen Y, Evans T, Chuang P, Das B, He JC. Novel retinoic acid receptor alpha agonists for treatment of kidney disease. PLoS One 2011, 6(11):e27945. 10.1371/journal.pone.0027945, 3220717, 22125642.
90. Vaughan MR, Pippin JW, Griffin SV, Krofft R, Fleet M, Haseley L, Shankland SJ. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 2005, 68(1):133-144. 10.1111/j.1523-1755.2005.00387.x, 15954902.
91. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006, 17(12):3382-3393. 10.1681/ASN.2006050520, 17082242.
92. Klaus G. Renoprotection with vitamin D: specific for diabetic nephropathy?. Kidney Int 2008, 73(2):141-143. 10.1038/sj.ki.5002693, 18165810.
93. Wang Y, Zhou J, Minto AW, Hack BK, Alexander JJ, Haas M, Li YC, Heilig CW, Quigg RJ. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 2006, 70(5):882-891. 10.1038/sj.ki.5001624, 16820793.
94. Deb DK, Wang Y, Zhang Z, Nie H, Huang X, Yuan Z, Chen Y, Zhao Q, Li YC. Molecular mechanism underlying 1,25-dihydroxyvitamin D regulation of nephrin gene expression. J Biol Chem 2011, 286(37):32011-32017. 10.1074/jbc.M111.269118, 3173158, 21803771.
95. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, Kong J, Quigg RJ, Li YC. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008, 73(2):163-171. 10.1038/sj.ki.5002572, 17928826.
96. Bertocchio JP, Jaisser F. Aldosterone and kidney diseases: an emergent paradigm with important clinical implications. Nephrol Ther 2011, 7(3):139-147. 10.1016/j.nephro.2010.10.012, 21144811.
97. Briet M, Schiffrin EL. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010, 6(5):261-273. 10.1038/nrneph.2010.30, 20234356.
98. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98(4):1063-1068. 10.1172/JCI118867, 507523, 8770880.
99. Nishiyama A, Yoshizumi M, Rahman M, Kobori H, Seth DM, Miyatake A, Zhang GX, Yao L, Hitomi H, Shokoji T, et al. Effects of AT1 receptor blockade on renal injury and mitogen-activated protein activity in Dahl salt-sensitive rats. Kidney Int 2004, 65(3):972-981. 10.1111/j.1523-1755.2004.00476.x, 2573027, 14871417.
100. Sun GP, Kohno M, Guo P, Nagai Y, Miyata K, Fan YY, Kimura S, Kiyomoto H, Ohmori K, Li DT, et al. Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006, 17(8):2193-2201. 10.1681/ASN.2005121375, 16790507.
101. Yaoita E, Kawasaki K, Yamamoto T, Kihara I. Variable expression of desmin in rat glomerular epithelial cells. Am J Pathol 1990, 136(4):899-908. 1877632, 2183627.
102. Yan K, Kudo A, Hirano H, Watanabe T, Tasaka T, Kataoka S, Nakajima N, Nishibori Y, Shibata T, Kohsaka T, et al. Subcellular localization of glucocorticoid receptor protein in the human kidney glomerulus. Kidney Int 1999, 56(1):65-73. 10.1046/j.1523-1755.1999.00503.x, 10411680.
103. Guess A, Agrawal S, Wei CC, Ransom RF, Benndorf R, Smoyer WE. Dose- and time-dependent glucocorticoid receptor signaling in podocytes. Am J Physiol Renal Physiol 2010, 299(4):F845-F853. 10.1152/ajprenal.00161.2010, 2957255, 20630936.
104. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006, 58(4):726-741. 10.1124/pr.58.4.5, 17132851.
105. Boulanger H, Mansouri R, Gautier JF, Glotz D. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies?. Nephrol Dial Transplant 2006, 21(10):2696-2702. 10.1093/ndt/gfl448, 16880183.
106. Ruan X, Zheng F, Guan Y. PPARs and the kidney in metabolic syndrome. Am J Physiol Renal Physiol 2008, 294(5):F1032-F1047. 10.1152/ajprenal.00152.2007, 18234957.
107. Letavernier E, Perez J, Joye E, Bellocq A, Fouqueray B, Haymann JP, Heudes D, Wahli W, Desvergne B, Baud L. Peroxisome proliferator-activated receptor beta/delta exerts a strong protection from ischemic acute renal failure. J Am Soc Nephrol 2005, 16(8):2395-2402. 10.1681/ASN.2004090802, 15944338.
108. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393(6687):790-793. 10.1038/31701, 9655393.
109. Inoue H, Tanabe T. Transcriptional role of the nuclear factor kappa B site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. Biochem Biophys Res Commun 1998, 244(1):143-148. 10.1006/bbrc.1998.8222, 9514889.
110. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274(45):32048-32054. 10.1074/jbc.274.45.32048, 10542237.
111. Kam RK, Deng Y, Chen Y, Zhao H. Retinoic acid synthesis and functions in early embryonic development. Cell Biosci 2012, 2(1):11. 10.1186/2045-3701-2-11, 3325842, 22439772.
112. Okamura M, Takano Y, Saito Y, Yao J, Kitamura M. Induction of nephrin gene expression by selective cooperation of the retinoic acid receptor and the vitamin D receptor. Nephrol Dial Transplant 2009, 24(10):3006-3012. 10.1093/ndt/gfp243, 19474283.
113. Han SY, So GA, Jee YH, Han KH, Kang YS, Kim HK, Kang SW, Han DS, Han JY, Cha DR. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004, 82(6):568-576. 10.1111/j.1440-1711.2004.01287.x, 15550114.
114. Morath C, Dechow C, Lehrke I, Haxsen V, Waldherr R, Floege J, Ritz E, Wagner J. Effects of retinoids on the TGF-beta system and extracellular matrix in experimental glomerulonephritis. J Am Soc Nephrol 2001, 12(11):2300-2309.
115. Simonson MS. Anti-AP-1 activity of all-trans retinoic acid in glomerular mesangial cells. Am J Physiol 1994, 267(5 Pt 2):F805-F815.
116. Na SY, Kang BY, Chung SW, Han SJ, Ma X, Trinchieri G, Im SY, Lee JW, Kim TS. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB. J Biol Chem 1999, 274(12):7674-7680. 10.1074/jbc.274.12.7674, 10075655.
117. Chonchol M, Cigolini M, Targher G. Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. Nephrol Dial Transplant 2008, 23(1):269-274.
118. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358(9292):1500-1503. 10.1016/S0140-6736(01)06580-1, 11705562.
119. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71(1):31-38. 10.1038/sj.ki.5002009, 17091124.
120. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008, 74(10):1343-1353. 10.1038/ki.2008.453, 2737358, 18784644.
121. Tian J, Wang HP, Mao YY, Jin J, Chen JH. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J Int Med Res 2007, 35(3):338-345.
122. Reis JP, Loria CM, Sorlie PD, Park Y, Hollenbeck A, Schatzkin A. Lifestyle factors and risk for new-onset diabetes: a population-based cohort study. Ann Intern Med 2011, 155(5):292-299. 3491359, 21893622.
123. Li D, Ding J. Molecular mechanism of proteinuria caused progression of chronic renal disease. Beijing Da Xue Xue Bao 2010, 42(5):608-611.
124. Branisteanu DD, Leenaerts P, van Damme B, Bouillon R. Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol 1993, 94(3):412-417. 1534446, 8252801.
125. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001, 158(5):1733-1741. 10.1016/S0002-9440(10)64129-6, 3277319, 11337371.
126. Migliori M, Giovannini L, Panichi V, Filippi C, Taccola D, Origlia N, Mannari C, Camussi G. Treatment with 1,25-dihydroxyvitamin D3 preserves glomerular slit diaphragm-associated protein expression in experimental glomerulonephritis. Int J Immunopathol Pharmacol 2005, 18(4):779-790.
127. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001, 60(1):87-95. 10.1046/j.1523-1755.2001.00775.x, 11422740.
128. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004, 286(3):F526-F533. 10.1152/ajprenal.00316.2003, 14600034.
129. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998, 53(6):1696-1705. 10.1046/j.1523-1755.1998.00951.x, 9607202.
130. Zou MS, Yu J, Nie GM, He WS, Luo LM, Xu HT. 1, 25-dihydroxyvitamin D3 decreases adriamycin-induced podocyte apoptosis and loss. Int J Med Sci 2010, 7(5):290-299. 2934728, 20827429.
131. Zou MS, Yu J, Zhou JH, Nie GM, Ding DS, Luo LM, Xu HT, He WS. 1,25-Dihydroxyvitamin D3 ameliorates podocytopenia in rats with adriamycin-induced nephropathy. Intern Med 2010, 49(24):2677-2686. 10.2169/internalmedicine.49.4174, 21173542.
132. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012, 302(6):F647-F657. 10.1152/ajprenal.00090.2011, 22169009.
133. Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X, Kong J, Li YC. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007, 72(2):193-201. 10.1038/sj.ki.5002296, 17507908.
134. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979, 206(4423):1188-1190. 10.1126/science.505004, 505004.
135. Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, Wong KE, Kong J, Li YC. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-{kappa}B pathway. Am J Physiol Renal Physiol 2009, 296(5):F1212-F1218. 10.1152/ajprenal.00002.2009, 2681355, 19193728.
136. Takano Y, Yamauchi K, Hiramatsu N, Kasai A, Hayakawa K, Yokouchi M, Yao J, Kitamura M. Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol 2007, 292(5):F1573-F1582. 10.1152/ajprenal.00423.2006, 17244893.
137. Kim JE, Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes 2004, 53(11):2748-2756. 10.2337/diabetes.53.11.2748, 15504954.
138. Finn AV, John M, Nakazawa G, Polavarapu R, Karmali V, Xu X, Cheng Q, Davis T, Raghunathan C, Acampado E, et al. Differential healing after sirolimus, paclitaxel, and bare metal stent placement in combination with peroxisome proliferator-activator receptor gamma agonists: requirement for mTOR/Akt2 in PPARgamma activation. Circ Res 2009, 105(10):1003-1012. 10.1161/CIRCRESAHA.109.200519, 19797172.